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ABSTRACT: In this work, multifunctional nanocarriers consisting of
poly(sodium-4-styrenesulfonate) (PSS)/doxorubicin (DOXO)/poly-L-lysine
hydrobromide (PLL)/hyaluronic acid (HA)-coated and (PSS/DOXO/
PLL)2/HA-coated gold nanorods were assembled by the layer-by-layer
technique with the aims of coupling the plasmonic photothermal properties
of the metal nanoparticles for plasmonic hyperthermia and the chemoaction
of drug DOXO for potential intended combinatorial cancer therapeutics in
the future as well as providing different strategies for the controlled and
sustained release of the cargo drug molecules. To do that, DOXO could be
successfully loaded onto the hybrid nanoconstructs through electrostatic
interactions with high efficiencies of up to ca. 78.3 ± 6.9% for the first
formed drug layer and 56 ± 13% for the second one, with a total efficiency
for the whole system [(PSS/DOXO/PLL)2/HA-coated NRs] of ca. 65.7 ±
1.4%. Nanohybrid internalization was observed to be enhanced by the outer
HA layer, which is able to target the CD44 receptors widely overexpressed in some types of cancers as lung, breast, or ovarian
ones. Hence, these nanohybrid systems might be versatile nanoplatforms to simultaneously deliver sufficient heat for therapeutic
plasmonic hyperthermia and the anticancer drug. Two controlled mechanisms were proposed to modulate the release of the
chemodrug, one by means of the enzymatic degradable character of the PLL layer and another by the modulation of the
interactions between the polymeric layers through the exploitation of the optical properties of the hybrid particles under near
infrared (NIR) laser irradiation. The combination of this bimodal therapeutic approach exerted a synergistic cytotoxic effect on
both HeLa and MDA-MB-231 cancer cells in vitro. Cell death mechanisms were also analyzed, elucidating that plasmonic
photothermal therapy induces cell necrosis, whereas DOXO activates the cell apoptotic pathway. Therefore, the present NIR
laser-induced targeted cancer thermo/chemotherapy represents a novel targeted anticancer strategy with easy control on
demand and suitable therapeutic efficacy.
1. INTRODUCTION
Cancer is a disease characterized by the uncontrolled growth
and spread of abnormal cells originated from inherited DNA
damage or induced by environmental factors and is the second
cause of death worldwide. For example, 1 688 780 new cancer
cases and 600 920 cancer deaths were estimated in 2017 only
in USA.1 Current cancer treatments include surgery, chemo-
therapy, and/or radiation. Surgical extirpation is highly
effective in primary tumors, but it is limited to surgically
recognizable and accessible tumors and thus cancer cells may
not be completely removed. Radiation (X-rays, gamma rays, or
electrons) is often used to destroy diseased cell and tissues at
the molecular level as a complementary approach to eradicate
remaining cancer cells after surgery. However, it may cause
damages to healthy tissues located close to cancerous cells or
within the pathway of the radiation beam. On the other hand,
the systematic administration of chemical drugs to kill
malignant cells (chemotherapy) is sometimes effective for
complete tumor elimination and subsequent patient recovery,
but it possesses numerous drawbacks and adverse side effects,
for example, (i) side toxicity in healthy tissues as a result of its
nonspecificity; (ii) development of drug resistances; (iii)
achievement of suboptimal therapeutic concentrations in the
diseased cells/tissues as a consequence of poor drug diffusion
and accumulation conditioned by tumor structure and
vascularization; and so forth. In addition, the impossibility of
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an early detection of very small tumors or blood circulating
malignant cells also decreases the probability of success of
current cancer therapies. Therefore, alternative treatments/
therapies are largely required.
A strategy to overcome the aforementioned drawbacks can
be the combination of antitumor drugs with colloidal
nanoparticles (NPs) used as nanocarriers or nanoreservoirs,
which emerges as an interesting area of research to overcome
the limitations, for example, of current chemotherapies.2 Drug
nanocarriers possess several advantages over free drugs,
including (i) their nanometer size, which can exploit the
physiological abnormalities of tumoral cells/tissues to favor
their selective accumulation in the diseased areas through the
enhanced permeation and retention effect;3 (ii) their capability
to transport high drug payloads with prolonged half-life and
reduced toxicity, thus significantly lowering the therapeutic
dose required for effective treatment (IC50);
4 (iii) their ability
to evade the immune system;4,5 and (iv) their potential for
selective targeting cancer cells and tissues thanks to their
potential high surface density to attach specific ligands which
can bind to overexpressed receptors in cancerous cells (the so-
called active targeting).5
Several types of NPs have been already proved for effective
anticancer therapies including micelles;6 liposomes;7 polymeric
NPs;8 dendrimers;9 carbon-based nanostructures as carbon
nanotubes;10 gold,11 silver,12 and iron oxide NPs;13 semi-
conductor quantum dots;14 and viral capsids.15 Among all
these types of particles, gold (Au) NPs (nanospheres,
nanorods, nanoshells, nanocages, and nanostars) are gaining
great importance for several reasons as follows: (i) Au NPs are
considered to be relatively nontoxic and nonreactive and are
therefore suitable for in vivo applications;16 (ii) they exhibit
outstanding optical properties, for example, the generation of
localized surface plasmons;17 (iii) their nature allows the facile
addition of new surface functionalities;18 and (iv) their size,
morphology, and monodispersity can be easily controlled
during the synthesis process, allowing the fine-tuning of their
optical properties from the visible to the near-infrared region
(NIR) region of the electromagnetic spectrum.19
Compared with other available Au NPs, Au nanorods
(GNRs) are especially attractive as a consequence of their
anisotropic structure. This morphology allows the collective
coherent oscillation of conduction electrons on the particle
surface upon interaction with light of suitable wavelength to
occur mainly in two directions, that is, along the short and long
axes of the NP, resulting in the generation of the so-called
transverse and longitudinal localized surface plasmon bands
(LPSRs).20 The subsequent main relaxation process usually
involves a high conversion of light into heat, which is released
to the medium. The GNR transverse LPSR band usually
appears in the visible region of the electromagnetic spectrum,
whereas the longitudinal one usually appears in the NIR, that
is, within the so-called first biological window, which makes
this type of particles really interesting for biological
applications.21 GNRs also exhibit the most suitable NIR
absorption cross sections if compared with other Au NPs,22
demonstrating extremely efficient NIR photothermal heat
conversion while reducing both the energy required for
phototreatment ( thus minimizing the affectation of surround-
ing healthy tissues) and photobleaching.23 The generated
thermal energy can induce temperature increases of more than
20 °C (i.e., hyperthermia), which can thereby induce
therapeutic tumor/cell tissue ablation (above 43−45 °C) or
thermal tissue sensitization (below 43 °C) to optimize the
efficacy of complementary therapies such as chemo- or
radiotherapies.24,25 In this regard, NIR plasmonic photo-
thermal therapy (PPTT) using GNRs was first demonstrated
by El-Sayed’s group, who showed the destruction of cancer
cells after exposure to a focused NIR light beam without
affectation of healthy ones.26 Other researchers also demon-
strated the same great feasibility of tumor photothermal
ablation using different types of gold, other metal, and organic
NPs.25,27−29 Moreover, it is worth noting that GNRs possess
much larger surface areas per volume than that of, for example,
spherical Au NPs, which make them an attractive nanocarrier
with large payload capability for codelivering several types of
therapeutical agents as antibodies,30 chemotherapeutic drugs,31
or nucleic acids.32 To do this, suitable modification of the
particle surfaces by different strategies such as ligand
exchange,33 hydrophobic/electrostatic adsorption,34 layer-by-
layer (LbL) assembly,35 or silica coating36 is required, which
also enables the controlled release of the payloads either by
internal (pH, enzymes, temperature, etc) or external (light,
ultrasounds, electric and magnetic fields, etc.) stimuli without
compromising the particle stability in biological fluids. Then, it
is expected that the combination of PPTT provided by the
plasmonic properties of GNRs and chemotherapy would be
able to provide synergistic therapeutic benefits in the treatment
of tumoral cells and a way to overcome multidrug resistances.37
For these reasons, in this work, we developed a therapeutical
nanocarrier based on the exploitation of the plasmonic
properties of GNRs and their easy surface modification by
the LbL assembly technique to allow the loading of large
amounts of the chemodrug doxorubicin (DOXO), while
ensuring a high colloidal stability in biological fluids, a
controlled and sustained release of the cargo, and high cell
uptake and internalization levels. DOXO is an anthracycline
antibiotic widely used to treat a wide range of cancers by
intercalating DNA and inhibiting macromolecular biosynthesis.
Like other anticancer drugs, several drawbacks are associated
to its periodical administration such as poor selectivity,38 dose-
dependent cardiotoxicity,39 and/or the induction of multidrug
resistances in cancer cells40 so that new forms of admin-
istration are largely required.
Here, GNRs were obtained by a wet seed-mediated chemical
reduction method.26 The resulting particles were coated with
alternating layers of the anionically charged poly(styrene
sulfonate) (PSS) and the cationically charged poly(lysine)
(PLL) polymers to mask the toxic hexadecyltrimethyl
ammonium bromide (CTAB) layer resulting from the
synthesis process after a preliminary washing step.34,35
DOXO was introduced in the assembled surface coating in
the form of one or two layers by exploiting the electrostatic
interactions with the underlying PSS layer. Finally, hyaluronic
acid (HA) was used as the outer external polymeric layer
thanks to their ability to avoid nonspecific interactions with
serum components41 as well as to target and bind overex-
pressed CD44 receptors in some types of cancerous cells, such
as cervical HeLa and breast MDA-MB-231, allowing an active
targeting strategy to localize the hybrid particles within the
diseased cells/tissues.42 Thanks to the clever choice of the
coating polymers, drug release could be triggered either by
means of the enzymatically biodegradable character of the PLL
polymer and/or by exploitation of the NIR optical properties
of GNRs, which enable the modulation of the attraction
between the polymeric layers at the surface particle coating
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under NIR light irradiation by controlling the size of the
illuminated area, exposure time, and light fluency. Additionally,
the combination of the generated NIR-induced hyperthermia
and the controlled and sustained release of the chemodrug
might allow the obtention of combinatorial synergistic
therapeutical effects provided by the cell-internalized hybrid
nanoplatforms as elucidated from transmission electron
microscopy (TEM), flow cytometry, and fluorescence
microscopy in vitro experiments.
2. RESULTS AND DISCUSSION
2.1. DOXO Entrapment. GNRs were prepared through
the well-established two-step seed-mediated growth method
with slight modifications (see Experimental Section).26 The
resulting GNRs exhibit a size of 33 nm × 9 nm. To mask the
CTAB layer and avoid their associated toxicity as well as the
provide the obtained metallic NPs with sufficient colloidal
stability, triggered controlled cargo release, and active targeting
abilities, NP surfaces were modified by means of the LbL
assembly technique. In this manner, using the LbL method,
multilayers of the polyelectrolyte (PE) anionic PSS, cationic
PLL, and anionic HA as well as the chemodrug DOXO were
successfully deposited onto the GNR surfaces.
Herein, CTAB facilitated the electrostatic adsorption of the
anionic PSS PE. The same interactions were further used for
the subsequent adsorption of the positively charged DOXO by
exploiting the protonation of the amino group in the sugar base
moiety of its molecular structure.43 To achieve complete
charge reversal, an additional cationic PLL layer was deposited.
Finally, a last layer of HA was associated to decrease the net
positive electrical charge of the hybrid nanoconstruct to avoid
potential toxic effects and to provide specific targeting to
CD44 receptors commonly overexpressed in the membrane
surfaces of several types of malignant stem and cancerous
cells.42
Next, we evaluated the maximum amount of antineoplasic
able to be adsorbed within the particle coating in the form of a
single drug layer. To do that, different amounts of DOXO were
assembled via LbL to PSS-coated GNRs previously prepared.
The successful loading of the cargo onto the metallic NPs was
confirmed by UV−vis spectrophotometry. Figure S1 confirms
the presence of the characteristic absorption peak of DOXO at
ca. 490 nm, which becomes more intense as more DOXO is
adsorbed onto the metallic NPs. Moreover, a progressive red
shift of the longitudinal LPSR band of GNRs is also observed
as a consequence of changes in the local dielectric environment
of the NPs as more drug is located near the metal surface.
The loading capacities (LCs) and entrapment efficiencies
(EEs) of DOXO on PSS-coated GNRs at different initial fed
DOXO (IFD) concentrations are displayed in Table 1. From
150 μg of initial fed drug, the loaded DOXO amount is almost
constant, suggesting that the saturation of the particle surface
was achieved, with averaged LCs of ca. 65% (∼80 μg DOXO
in 1 mL GNRs at 1 × 1011 NP/mL) and EEs of ca. 80%. This
is in agreement with the progressive increase in the observed
negative particle ζ-potential values up to ca. 150 μm fed drug
and their subsequent leveling off at larger DOXO concen-
trations (Figure S1b). Thus, for further experiments, we
decided to use 150 μg as the IFD.
2.2. Characterization of DOXO-Loaded GNRs. Once
the ability of DOXO to self-assemble on the GNR surfaces by
the LbL technique was confirmed, then, the construction of
DOXO-loaded GNRs bearing one (denoted as PSS/DOXO-
PLL/HA-coated GNRs) or two DOXO [denoted as (PSS/
DOXO-PLL)2/HA-coated GNRs] coating layers was afforded
(see Scheme 1). The latter nanoconstruct was designed to
additionally enhance the loaded DOXO concentration in the
nanoplatform. These coated GNRs were characterized by UV−
vis spectroscopy, ζ-potential measurements, dynamic light
scattering (DLS), and TEM.
Figure 1a,b shows the UV−vis spectra after each deposition
step for (PSS/DOXO/PLL)2/HA-coated GNRs. It was
observed that the longitudinal plasmon absorption peak of
GNRs shifts after PE adsorption as a consequence of the
extreme sensitivity of the particles to the dielectric properties
of the surrounding environment,43 thus confirming the
successful layer adsorption. Any coating onto the NP surfaces
involves a change in the dielectric properties of the particle
surroundings, giving rise to a similar effect as immersing the
particles in a continuous medium of different refractive indexes
(RIs) and hence shifting the position of the longitudinal LSPR
maximum (see below). DOXO absorption was confirmed by
the enhancement of the band located at 490 nm, which
increases with the number of DOXO layers (Figure 1b).
Moreover, a relative small broadening of the absorption bands
after layer depositions was noted, particularly after the first
lysine deposited layer, which suggests the presence of some
minimal particle aggregation after the successive coating steps.
For DOXO, PLL, and HA coating layers, a red shift in the
longitudinal LSPR band is observed; particularly, for PLL, this
red shift might be also influence by some interparticle coupling
resulting from the slight observed particle aggregation. In
contrast, a blue shift is observed for the PSS coating (see
Figure 1b). Blue shifts of the plasmon bands after polymer
deposition have been related to polymer unwrapping,44 but
this is not the case as observed from the change from positive
to negative of ζ-potential values (Figure 1c). Hence, the
observed variations can be ascribed to the different RIs of the
PEs compared to that of the CTAB surfactant.45 On the other
hand, a certain damping of the longitudinal LPSR peak
progressively took place as more polymeric layers are added on
the GNR surfaces (see Figure 1a,b). This effect can be the
Table 1. DOXO EE and LC on PSS-Coated GNRs (∼1 ×
1011 NP/mL) through the LbL Assembly Technique as a
Function of the IFD Mass
IFD (μg) loaded drug (μg) EE (%) LC (%)
50 2.70 ± 0.81 5.4 5.9
100 33.5 ± 4.6 16.8 43.8
150 76.3 ± 1.0 76.3 64.0
200 86.6 ± 1.2 57.7 66.9
300 78.6 ± 3.6 26.2 64.7
Scheme 1. Schematic Representation of PSS/DOXO/PLL/
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result of a reduction of (i) the adsorption of part of the
incoming light and/or (ii) the electronic oscillations on the
metallic surface.46 Conversely, the absorbance corresponding
to the transversal plasmon band is barely constant except when
DOXO is adsorbed, where a certain increment is noted (Figure
1b) as a consequence of the contribution of the drug
absorption peak at ca. 490−495 nm.
ζ-Potential data (Figure 1c) revealed a reversal in the
electrical surface charge of GNRs after the deposition of each
adsorbed layer except for DOXO one, as mentioned above.
The characteristic zig-zag profile corroborates the layering of
alternatively charged PEs with two intermediate drug layers.
The assembly of the last HA layer was designed taking into
consideration that slightly positively charged NPs should be
more effective in interacting with the negatively charged cell
membranes, as mentioned in previous chapters.35,47 Therefore,
the amount of HA incorporated was such to decrease the net
positive surface charge of the NPs while avoiding complete
charge reversal.
Figure 2 shows the population hydrodynamic size
distributions measured by DLS for PSS/DOXO/PLL/HA-
coated and (PSS/DOXO/PLL)2/HA-coated GNRs. Here, it is
necessary to bear in mind that DLS data are calculated on the
assumption of spherical geometries so the obtained hydro-
dynamic radii should be taken as a bare approximation. The
hydrodynamic dimensions of the hybrid nanoplatforms
increased as the number of wrapped layers did (e.g., a single
PSS layer led to a size increase of ca. 5 nm), and particle sizes
increased up to ca. 77.0 ± 4.5 and 151.3 ± 7.1 nm for PSS/
DOXO/PLL/HA-coated GNRs and (PSS/DOXO/PLL)2/
Figure 1. (a) UV−vis absorbance spectra for each PE layer deposited onto GNRs for (a) (PSS/DOXO/PLL)2/HA-coated GNRs. (b) Longitudinal
LSPR shifts (black ●), longitudinal (red ■) and transversal (red □) absorbance decays, and (c) ζ-potentials (black ■) after each coating step for
(PSS/DOXO/PLL)2/HA-coated GNRs. The LSPR shift of coated GNRs with layer i is defined as Δλ = λ(i) − λ(CTAB). Longitudinal and
transversal decays are constructed as the ratio between the optical absorbance in layer i regarding that of the CTAB layer: decay(SPR) = abs(i)/
abs(CTAB). The lines are only to guide the eye.
Figure 2. Hydrodynamic radii for (a) CTAB-coated (black), PSS-coated (red), PSS/DOXO/PLL-HA-coated (blue), and (PSS/DOXO/PLL)2-
HA-coated (green) GNRs. (b) Scanning TEM image of (PSS/DOXO/PLL)2/HA-coated GNRs.
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HA-coated ones, respectively. These size increments might be
especially related to the swelling of the outer HA layer in
aqueous environments,48 but some little clusterization of the
nanoplatforms cannot be completely disregarded. To note
some potential contribution from particle aggregation or
bridging between GNRs, TEM images were also acquired.
Almost negligible signs of aggregation and/or bridging were
noted. The coating layers were hardly observed, provided that
they did not offer enough contrast.
Next, the EE for a chosen initial feed of 150 μg of DOXO in
1 mL of PSS-coated GNRs at OD ≈ 1 (ca. 5 × 1014 NP/mL)
was estimated to be ca. 78.3 ± 6.9% for the first layer of the
adsorbed drug and 56 ± 13% for the second one, with a total
EE of ca. 65.7 ± 1.4% for (PSS/DOXO/PLL)2/HA-coated
GNRs. Similar decreases in EE upon sequential entrapment of
drugs in several layers have been also reported elsewhere.49
The LCs were 41.5 ± 7.9 and 39.4 ± 5.4% for the first and
second drug layers, respectively, with a whole LC of 51 ± 13%,
which highlights the outstanding capacity of these hybrid
nanoplatforms to entrap DOXO in the polymeric surface
layers.
2.3. DOXO Release from Hybrid GNRs. We next
determined the in vitro cumulative DOXO release profiles
from PSS/DOXO/PLL/HA-coated and (PSS/DOXO/PLL)2/
HA-coated GNRs at different conditions, in particular, at
physiological pH 7.4 and pH 5.5, which correspond to the
acidic microenvironment of the cell cytoplasm, in the presence
of 10% (v/v) fetal bovine serum (FBS). Moreover, the
influence of both endogenous and exogenous triggers as
enzymes (proteases) and NIR light in the drug release profiles
and rates was also analyzed.
2.3.1. Enzymatic-Assisted Drug Release. The biodegrad-
ability of the PLL polymer by endogenous proteases such as
lysosomal cathepsin B, often upregulated in cancerous and
inflamed cells, and trypsin may confer a slow degradation of
the polymeric layer inside the cells and enable a gradual
triggered DOXO release from the particles, which might result
in a sustained therapeutic effect at much lower doses than that
of the administered free drug.
To study DOXO release from both PSS/DOXO/PLL/HA-
coated and (PSS/DOXO/PLL)2/HA-coated GNRs, the hybrid
particles were incubated at 37 °C in the presence and absence
of trypsin at both pHs 7.4 and 5.5 supplemented with 10% (v/
v) FBS for 4 days (Figure 3). The release profiles initially
displayed a burst phase followed by a much slower release
pattern for both types of drug-loaded particles at both solution
conditions. At pH 7.4 in the absence of the enzyme, PSS/
DOXO/PLL/HA-coated GNRs released ca. 50% of the loaded
cargo in 96 h, whereas (PSS/DOXO/PLL)2/HA-coated ones
only released ca. 35% (Figure 3a), in agreement with the much
slower drug diffusion from the inner coating layer. In the
presence of trypsin, PSS/DOXO/PLL/HA-coated GNRs
released ca. 85% of the cargo, whereas (PSS/DOXO/PLL)2/
HA-coated ones released ca. 50%, which agrees with (i) the
degradation of PLL when the protease is present, thus
facilitating drug diffusion out of the particles and (ii) the
larger resistance of the (PSS/DOXO/PLL)2/HA coating layer
to enzymatic degradation, offering an enhanced cargo
protection and lowering the release rate.50,51 An additional
contribution to drug diffusion at physiological pH might also
stem from the reduced ionization state of the drug (pKa of
DOXO ca. 8.2), which results in a weakening of electrostatic
interactions with the underlying anionic PSS polymeric layer.51
Under acidic conditions (see Figure 3b), DOXO cumulative
releases from the hybrid particles were much slower. For
example, in the presence of trypsin, DOXO released after 96 h
reached ca. 40 and 20% for PSS/DOXO/PLL/HA-coated and
(PSS/DOXO/PLL)2/HA-coated GNRs, respectively, in con-
trast to 85 and 50% at physiological pH. In addition,
differences in DOXO release rates and extents from PSS/
DOXO/PLL/HA-coated and (PSS/DOXO/PLL)2/HA-
coated GNRs in the presence and absence of the enzyme
were much smaller. Several factors may contribute to the
observed behavior. At pH 5.5, PLL is more densely charged
and adopts a random coil conformation,52 which should
facilitate the establishment of electrostatic interactions and
entanglements with the underlying PSS layer, compacting the
PE coating and thus reducing drug diffusion. Moreover,
DOXO molecules are positively charged at acidic pH, favoring
the attraction with the PSS layer/s. This effect is specially
noted for (PSS/DOXO/PLL)2/HA-coated GNRs, in which
the accessibility of the enzyme to the PE coating within the
time range analyzed seemed to be largely precluded. In
summary, the release rates were generally faster in the presence
of the degrading enzyme as a consequence of PLL degradation,
and the amount of released drug depended on the number of
layers covering the particles and the solution conditions.53
2.3.2. NIR Light-Induced Release. The possibility of
triggering DOXO release from the hybrid NPs by using NIR
light irradiation matching the longitudinal LPSR peak of GNRs
Figure 3. DOXO cumulative release profiles at (a) pH 7.4 and (b) pH 5.5 for PSS/DOXO/PLL/HA-coated (squares) and (PSS/DOXO/PLL)2/
HA-coated GNRs (circles) in the absence (black ■, red ●) and presence (black □, red ○) of trypsin. The lines are only to guide the eye. The
relative standard deviation (SD) was found less than 10.0%. Error bars were not included for clarity.
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was also explored. Hence, in vitro cumulative DOXO release
profiles at acidic conditions (pH 5.5) in the presence of 10%
(v/v) FBS under NIR laser irradiation of 808 nm and fluencies
of 0.5 and 3.0 W/cm2 applied for 5 min at 6 and 24 h of
incubation were obtained (Figure 4).
Similar to enzymatic-assisted release, NIR-induced DOXO
release profiles displayed a burst phase at short incubation
times (within ca. 12−20 h of incubation) followed by a more
sustained release phase. The release extent was observed to be
greatly enhanced in the presence of NIR light irradiation
compared to protease-assisted and diffusion-only cumulative
releases for both types of hybrid particles (Figure 4). For
example, meanwhile the PLL coating was hardly degraded by
trypsin at short incubation times (<24 h), laser irradiation
achieved a much faster destabilization of the PE layers through
localized heating around each NP and the potential generation
of hot electrons, which modifies PE−drug interactions and
allows DOXO release.54 For PSS/DOXO/PLL/HA-coated
GNRs (Figure 4a), the release extent and rate were slightly
larger under NIR illumination of 3 W/cm2 than those at 0.5
W/cm2, with ca. 65 and 60% of drug release after 96 h of
incubation, respectively. Light-induced DOXO release from
(PSS/DOXO/PLL)2/HA-coated GNRs was ca. 37% with no
influence of the applied light intensity and lower than those
obtained for the former types of particles (Figure 6b). We
hypothesized that light absorption by the multilayered
structure (see above) might involve the used fluencies to be
insufficient to correctly modulate the PE interactions (Figure
6b).
2.4. Particle Uptake and DOXO Release in Vitro. The
uptake and cellular distribution of PSS/DOXO/PLL/HA-
coated and (PSS/DOXO/PLL)2/HA-coated GNRs were
analyzed by fluorescence microscopy in the absence and
presence of NIR light irradiation (0.5 W/cm2, 5 min) for 24 h
by taking advantage of the intrinsic fluorescent properties of
DOXO. As an additional control, PSS/PLL/HA-coated GNRs
were used to disregard any potential interference from light
reflection originated by the hybrid particles. In this manner, the
red fluorescence could be solely assigned to the presence of the
drug.
Figure 5 shows that both PSS/DOXO/PLL/HA-coated and
(PSS/DOXO/PLL)2/HA-coated GNRs were internalized by
HeLa cells, as observed for the red fluorescence corresponding
to DOXO released inside the cells, similar as that observed for
the administered free drug used as the reference. In the
absence of NIR light irradiation, free DOXO is able to
penetrate the cell nuclei within 4 h of incubation. Fluorescent
signals of DOXO released from PSS/DOXO/PLL/HA-coated
and (PSS/DOXO/PLL)2/HA-coated GNRs were less intense
at this time point and mainly located in the cell cytoplasm,
which agrees with the slower and sustained release of the drug
from the NPs (see Figure 3). It is known that DOXO can be
quickly transported into cells, entering the active site (nuclei)
by passive diffusion. In contrast, DOXO-loaded GNRs are
internalized in cells by an endocytosis-related mechanism and
are too large to cross the membrane of cell nuclei so only
released DOXO from particles can diffuse into.55 This fact was
corroborated through three-dimensional (3D) image recon-
struction of cells upon incubation with (PSS/DOXO/PLL)2/
Figure 4. NIR-induced DOXO release from (a) PSS/DOXO/PLL/HA-coated and (b) (PSS/DOXO/PLL)2/HA-coated GNRs. The laser powers
were 3.0 (green ▼) and 0.5 (blue ▲) W/cm2. Simple drug diffusion (black ■, red ●) and enzymatic-assisted release (black □, red ○) are also
shown for comparison. The relative SD was found to be less than 10.0%. Error bars were not included for clarity. The lines are only to guide the
eye.
Figure 5. Fluorescence microscopy images of (from top to bottom):
bare HeLa cells, bare PSS/PLL/HA-coated GNRs, free DOXO, PSS/
DOXO/PLL/HA-coated GNRs, and (PSS/DOXO/PLL)2/HA-
coated GNRs after 4 h of internalization. The blue channel shows
the fluorescence from cell nuclei stained with 4′,6-diamidino-2-
phenylindole (DAPI; λex = 355 nm); the red channel shows the
DOXO fluorescence signal; the TL-BF channel displays the optical
direct bright field images; and the merged images show the
combination of the three previous channels. Scale bars are 10 μm.
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HA-coated GNRs for 6 h (see Figure S2 in Supporting
Information).
On the other hand, at longer incubation times (>6 h),
DOXO released from particles reached the cell nuclei and its
fluorescence became more important than that of free DOXO,
particularly after 24 h of incubation (see Figure S3 in
Supporting Information). This was especially noted for PSS/
DOXO/PLL/HA-coated GNRs; for (PSS/DOXO/PLL)2/
HA-coated ones, the observed intensity was slightly lower, in
agreement with their more sustained release pattern, as
observed previously (see Figure 3). Nonetheless, the presence
of DOXO in the cell cytoplasms at 24 h for both types of
hybrid nanoplatforms confirmed the sustained DOXO release
from the nanoconstructs.
Fluorescence images of cancerous cells with internalized
DOXO-loaded nanohybrids under laser light irradiation
suggested that NIR light exposure enhanced particle uptake
and drug release by modulating the electrostatic interactions
between DOXO and the polymeric layers.56 The presence of
DOXO in cell nuclei was observed faster under laser exposure,
as noted by the stronger red signals in nuclei at shorter
incubation times (6 h) and which was maintained at longer
times. No important differences in fluorescence signals
between PSS/DOXO/PLL/HA-coated and (PSS/DOXO/
PLL)2/HA-coated GNRs after 24 h of incubation under NIR
irradiation were observed. Here, it is necessary to bear in mind
that (PSS/DOXO/PLL/HA-coated and (PSS/DOXO/PLL)2/
HA-coated GNRs released ca. 40 and 25% of the total drug at
24 h, respectively, but the bilayered nanohybrid is able to
encapsulate more drug; thus, the DOXO concentration
administered to cells under irradiation should be relatively
similar in both cases.
2.5. In Vitro Cell Cytotoxicity of DOXO-Loaded GNRs.
The cytotoxicity of the two different DOXO-loaded GNRs was
assessed by means of the CCK-8 proliferation assay.
Incubation of free DOXO, PSS/DOXO/PLL/HA-coated
GNRs, (PSS/DOXO/PLL)2/HA-coated GNRs, and PSS/
PLL/HA-coated GNRs (control) was done for 24 and 48 h
in cervical HeLa and breast MDA-MB-231 tumoral cell lines at
different NP concentrations (see also Table S1 in Supporting
Information).
Control PSS/PLL/HA-coated GNRs were observed to be
safe and nontoxic, with cell viabilities above 95% for MDA-
MB-231 cells at 24 and 48 h and HeLa ones at 24 h (Figure
6a,c,d) at concentrations up to 2.5 × 1010 NP/mL. At larger
particle concentrations, cell viabilities decrease but were still
above 50%, an accepted limit to consider a material as
biocompatible. For HeLa cells after 48 h of incubation (Figure
6b), cell viability hardly remained above 50% at the most
diluted concentrations (below 2.5 × 1010 NP/mL).35 This
larger cell toxicity would be related to a larger particle uptake
mediated by a receptor-endocytosis process, in which CD44
receptors largely overexpressed on the membrane surfaces of
HeLa cells would interact with the HA coating of the hybrid
NPs, which might compromise cell function and viability (see
Figure S4 in Supporting Information).35,57 On the other hand,
DOXO-loaded GNRs exhibited a stronger cell toxicity, which
can be ascribed exclusively to the drug action. Specifically,
PSS/DOXO/PLL/HA-coated GNRs and (PSS/DOXO/
PLL)2/HA-coated ones (Figure 6a,b) exhibited similar
concentration-dependent toxicity profiles in HeLa cells, with
the former nanoconstructs being more toxic in agreement with
their observed faster drug release rates (see Figure 3). In
addition, survival cell rates in the presence of DOXO-loaded
hybrid particles were smaller than those for the free drug,
Figure 6. Cellular viability of PSS/DOXO/PLL/HA-coated (black ■), (PSS/DOXO/PLL)2/HA-coated (red ●), and PSS/PLL/HA-coated
GNRs (blue ▲) and free DOXO (green ▼) in (a,b) HeLa and (c,d) MDA-MB-231 cells after 24 and 48 h of incubation.
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suggesting that a sustained drug release pattern from the NPs is
much more effective for a therapeutic action, that is, similar cell
toxicities can be achieved using much lower drug concen-
trations (Table 2).
On the other hand, MDA-MB-231 cells seemed to be less
sensitive to DOXO at 24 and 48 h as suggested by the larger
IC50 values compared to those of HeLa cells. At low NP
concentrations (below 2.5 × 1010 NP/mL), similar concen-
tration-dependent toxicity profiles were observed for both
nanocarriers and the free drug. At higher NP concentrations,
PSS/DOXO/PLL/HA-coated GNRs again displayed larger
cell toxicities, as observed for HeLa cells.
2.6. In Vitro Potential Combined Effects of Chemo-
and Photothermal Therapies. To analyze the combinatorial
effect of PPTT and DOXO, CCK-8 viability assays were also
carried out in the presence of NIR light illumination. Free
DOXO and PSS/DOXO/PLL/HA-coated, (PSS/DOXO/
PLL)2/HA-coated, and PSS/PLL/HA-coated GNRs (as
control) were administered to HeLa and MDA-MB-231 cells
in the presence of NIR laser illumination (808 nm) at different
intensities (0.5, 1, 3 W/cm2) after 6 h of incubation for 5 min,
and the cell viabilities were analyzed after 24 and 48 h of
incubation (Figure 7). The NP concentration was set up at 2.5
× 1010 NP/mL.
First, it was noted that cell toxicity induced by free DOXO
slightly increases as the irradiation intensity does after 24 h.
This effect was related to small macroscopic temperature
increases under NIR light illumination (see Figure S5 in
Supporting Information), which would promote more efficient
drug diffusion inside cells by increasing tissue permeability and
sensitivity to the drug therapeutic action.58 At longer
incubation times, these changes were largely diminished as a
consequence of the saturation of the cytostatic activity of the
chemotherapeutic drug.
As shown previously, bare PSS/PLL/HA-coated GNRs were
completely nontoxic in the absence of NIR irradiation at the
selected concentration. In comparison, NIR laser illumination
of these NPs led to a noticeable increase in cell toxicity
because of local temperature increments generated by the
plasmonic hyperthermic effect (see Figure S5).59 Also, HeLa
cells exhibited lower cell viabilities than MDA-MB-231 ones as
Table 2. IC50 Values for Free DOXO, PSS/DOXO/PLL/
HA-Coated and (PSS/DOXO/PLL)2/HA-Coated GNRs in






24 h 48 h 24 h 48 h
free DOXO 4.2 0.2 7.0 1.6
DOXO-loaded GNRs <12.4 <14.4 4.9 1.3
(DOXO)2-loaded GNRs 4.1 <6.5 2.1 1.2
aUncertainties are estimated to be less than 10%. bIC50 concen-
trations obtained from DOXO-loaded GNRs and (DOXO)2-loaded
GNRs were calculated taking into account the percentage of drug
released at 24 or 48 h (see Figure 3).
Figure 7. Photothermal-induced toxicity of PSS/PLL/HA-coated (bare), PSS/DOXO/PLL/HA-coated (monolayer), and (PSS/DOXO/PLL)2/
HA-coated (bilayer) GNRs and free DOXO (DOXO) in (a) HeLa and (b) MDA-MB-231 cells. The cells were irradiated with a continuous-wave
(CW) laser at 808 nm at 0 (blue), 0.5 (light blue), 1 (light red), and 3 W/cm2 (red) for 5 min. The dotted (50%) and dashed lines (100%) are
only to guide the eye.
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a result of their larger particle uptakes as a consequence of the
larger overexpression of the HA receptor of the former type of
cells, as mentioned above.
Both PSS/DOXO/PLL/HA-coated and (PSS/DOXO/
PLL)2/HA-coated GNRs gave rise to NIR light intensity-
dependent cell toxicities, these being larger than those in the
absence of light illumination. This highlights a potential
synergetic effect between PPTT and chemotherapy, for
example, increments in cell toxicity from 80% to almost
100% for PSS/DOXO/PLL/HA-coated NPs and from 62 to
83% for (PSS/DOXO/PLL)2/HA-coated nanocarriers at 3 W/
cm2 in HeLa cells after 48 h of incubation. Despite the evident
influence of light, PSS/DOXO/PLL/HA-coated GNRs dis-
played again a faster toxic activity compared to (PSS/DOXO/
PLL)2/HA-coated ones as a consequence of their quicker
cargo release. Besides, the attenuated light absorption observed
in (PSS/DOXO/PLL)2/HA-coated GNRs by the presence of
a thicker polymeric shell would additionally screen both drug
release and light-to-heat conversion, contributing to their lower
cell cytotoxicities.
2.7. Cell Death. To determine by which pathway (either
necrosis or apoptosis) the present multifunctional nanoplat-
forms cause toxicity to cells, an Annexin V (AnnV)/7-
Aminoactinomycin D (7AAD) dead cell assay was performed.
AnnV is a protein that specifically binds to phosphatidyl serine,
a phospholipid that becomes exposed on the cell surface as a
result of apoptosis. 7AAD, on the other hand, is a fluorophore
that intercalates with DNA and is used to analyze loss of
membrane integrity during necrosis. HeLa and MDA-MB-231
cells were treated with PSS/DOXO/PLL/HA-coated, (PSS/
DOXO/PLL)2/HA-coated, and PSS/PLL/HA-coated GNRs
and free DOXO used as a positive control for apoptosis.
Untreated cells were the negative (live) control. After 6 h of
incubation with the hybrid NPs or the free drug, cells were
illuminated with a CW NIR laser light at several power
intensities (0, 0.5, 1, and 3 W/cm2) for 5 min. The proportion
of live, dead, and apoptotic cells was quantified by flow
cytometry after 24 h of incubation. Here, it is considered that
necrosis and apoptosis are different mechanisms of cell death,
according to Kerr et al,60 so both processes can be present
simultaneously, that is, 7-ADD fluorescence will only appear
when the membrane is disrupted and the Annexin V signal will
be always present in apoptotic cells. We did not focus on the
molecular mechanisms involved in the observed processes,
which will be the subject of a future study.
Cell death in free DOXO-treated cells was dominated by
apoptosis (ranging from 80 to 90%) both in the absence and
presence of NIR laser irradiation (Figure 8), denoting that
irradiation does not have an influence on the DOXO-induced
cell mechanism. A much smaller signal from 7-ADD was also
noted, but the percentage of gathered cells was always below
ca. 10−15%, which may be associated to secondary necrosis,
that is, the loss of membrane integrity by late apoptotic cells.61
Thus, it can be safely considered that the action of the
chemodrug is mainly through apoptosis. On the other hand,
PSS/PLL/HA-coated GNR-induced cell death in the absence
of light irradiation was similar as that of control cells,
corroborating their low toxicity. In the presence of NIR
irradiation and as the light fluency is increased, the extent of
necrotic cells was largely enhanced as a consequence of the
photothermal effect, especially at fluencies above 1 W/cm2
(under 5 min of illumination), which is characterized by
extensive membrane blebbing, budding, and endosome
expansion (see below). Similar necrotic-induced cell death
Figure 8. Ann V/7AAD death cell assay in (a) HeLa and (b) MDA-MB-231 cells. The percentage of cells displaying Annexin V fluorescence is
shown in dark orange, and the percentage of necrotic ones stained with 7-ADD is shown in light orange. PSS/DOXO/PLL/HA-coated
(monolayer), (PSS/DOXO/PLL)2/HA-coated (bilayer), and PSS/PLL/HA-coated GNRs were irradiated at several power intensities with a CW
NIR laser (808 nm). DOXO was used as a positive control for apoptotic cells. The untreated cells were used as a negative control. The dotted and
dashed lines are only to guide the eye.
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was also previously noted for other NIR-irradiated GNR-based
nanosystems for PPTT applications.62,63 Conversely, very
recently, NIR illumination for short times (2−4 min) of gold
nanoplates using a 1064 nm laser light was shown to induce
cell death by apoptosis, which is mediated by nuclear encoded
proteins Bak and Bax through the activation of the BH3-only
protein BID.61 Hence, it can be considered that the type of
predominant programmed cell death mechanism may depend
on different inter-related factors such as the illumination
conditions, cellular internalization and location, particle type
and concentration, and so forth.
In addition, experimental data confirmed that cell death
caused by PSS/DOXO/PLL/HA-coated and (PSS/DOXO/
PLL)2/HA-coated GNRs in the absence of NIR irradiation is
mainly driven through apoptosis thanks to the chemodrug
action. As NIR irradiation is applied and the fluency
progressively increased, cell apoptotic-induced mortalities
(generally between ca. 60−80% for HeLa and ca. 80−90%
for MDA-MB-231 cells up to 1 W/cm2) are also observed as
occurred, for example, for Au nanoshells,64 and necrosis is
progressively enhanced and added to the apoptotic effect of
DOXO.
From Figure 8, it can be also appreciated that the level of
necrotic cells in HeLa cells was higher than that in MDA-MB-
231 ones. For instance, at 3 W/cm2, HeLa cells exhibited a 7-
ADD fluorescence of ca. at 80% compared to ca. 60% for
MDA-MB-231 cells. This was probably a consequence of the
larger particle uptake by the former cell line, as mentioned
before: a larger GNR concentration into cells would lead to
higher temperatures and then to cell death through a necrotic
pathway.
The type of induced cell death and the confirmation of cell
particle internalization were also monitored by TEM imaging.
PSS/PLL/HA-coated and PSS/DOXO/PLL/HA-coated
GNRs were incubated in HeLa cells for 6 h at standard
conditions. Some cells were also irradiated with an 808 nm
CW laser for 5 min at 1 W/cm2.
PSS/PLL/HA-coated GNRs were observed to internalize
inside HeLa cells without any sign of associated cell toxicity
(see Figure S6a,b in Supporting Information). These particles
were located at the cell cytoplasm inside endosomal vesicles,
which agrees with a receptor-mediated endocytosis process
promoted by the binding between HA and membrane surface-
expressed CD44 receptors. Some membrane blebs related to
the dehydration process undergone by cells during sample
preparation were also observed, and neither shrinking nor cell
swelling was noted. In comparison, internalization of PSS/
DOXO/PLL/HA-coated GNRs was accompanied by budding
and cellular separation in apoptotic bodies (see Figure S6c,d in
Supporting Information) related to the beginning of an
apoptotic process associated to the DOXO chemotherapeutic
activity, further corroborating the flow cytometry data. The
hybrid particles were also observed inside vesicles, and some
membrane blebs were noted, as occurred for PSS/PLL/HA-
coated particles.
Conversely, when PSS/PLL/HA-coated GNRs were inter-
nalized inside HeLa cells and irradiated at a fluency of 1 W/
cm2 for 5 min, mitochondrial swelling and more membrane
blebs, characteristic of a necrotic process were observed65 in
agreement with the Annexin V/7AAD dead Cell assay (Figure
9a,b). The hybrid particles were localized inside vesicles and
their morphology appeared altered, that is, some of them
partially lost their typical cylindrical morphology to become
more spherical as a consequence of melting due to the
relatively high temperatures reached under laser exposure.65
These particle-loaded vesicles have larger sizes than those
observed in nonirradiated cells, probably associated to an
increase in the inner pressure upon light-induced heating. No
evident signs of budding, shrinking, or presence of apoptotic
bodies were observed.
Finally, the combination of DOXO and PPTT after PSS/
DOXO/PLL/HA-coated GNRs internalization and subse-
quent NIR irradiation involved simultaneous signs of both
apoptosis and necrosis in cells such as the observation of cell
dehydration (shrinkage), budding, and the presence of
apoptotic bodies and blebs inside and around cell membranes
corresponding to the chemotherapeutic activity of DOXO and
PPTT effect, respectively, which is also in agreement with the
Annexin V/7AAD dead data (Figure 9c,d.). Most part of the
observed particle-containing vesicles appeared expanded with
some melted GNRs present inside.
3. CONCLUSIONS
In this work, we successfully designed and obtained GNR-
based hybrid nanoplatforms as a potential tool for the
controlled delivery of the therapeutic cargo by different
internal and external triggers and to get potential combined
chemo- and photothermal therapeutic outcomes by making use
of the photothermal activity provided by the metal NPs under
NIR light illumination and the presence of a chemotherapeutic
agent (DOXO) assembled in the particle polymeric coating
layer. In this manner, GNRs were surface-functionalized with
PSS, PLL, DOXO, and HA by means of the LbL assembly
technique. HA was used as the final outer coating layer to
provide particle colloidal stabilization as well as to serve as a
targeting moiety to bind CD44 receptors overexpressed on the
surface of different types of cancerous cells. Single and dual
DOXO layers could be formed within the surface-assembled
PE layers of GNRs (PSS/PLL/DOXO/HA-coated and (PSS/
PLL/DOXO)2/HA-coated GNRs, respectively). Drug release
from the hybrid particles could be either enzymatically and/or
light-triggered thanks to the biodegradability of PLL in the
presence of proteases and the modulation of interactions in the
PE coating layer by light, respectively. In vitro microscopy
Figure 9. TEM images of HeLa cells after 6 h of incubation with (a,b)
PSS/PLL/HA-coated GNRs and (c,d) (PSS/DOXO/PLL)2/HA-
coated GNRs under irradiation with an 808 nm CW laser for 5 min at
1 W/cm2. Scale bars are 2 μm.
ACS Omega Article
DOI: 10.1021/acsomega.8b01591
ACS Omega 2018, 3, 12633−12647
12642
fluorescence and TEM imaging confirmed the successful cell
internalization of the hybrid nanoplatforms. The simultaneous
combination of chemotherapy and photothermal activity
within this single nanoplatform increased cell cytotoxicity
significantly. This fact might potentially help to overcome drug
resistances to chemotherapeutic agents by allowing the use of
much lower drug concentrations. Moreover, it was noted that
HA-ligand targeting enhanced the photothermal effect as a
result of NP accumulation in cells to greater extents. The type
of cell death mechanism was evaluated by the Annexin V/
7AAD dead cell assay and TEM. It was noted that PPTT
caused necrosis to cells, as observed by mitochondrial swelling
and membrane blebs by TEM, whilst DOXO activated
apoptosis. The present GNR-based nanohybrids might addi-
tionally be optimized for other multimodal cancer therapies,
and their optical properties might be exploited for therapy
monitorization and preliminary diagnosis, making these
nanosystems ideal nanomaterials for theranosis.
4. EXPERIMENTAL SECTION
4.1. Materials. CTAB for molecular biology, tetrachlor-
oauric acid (HAuCl4·3H2O), silver nitrate (AgNO3), sodium
borohydride (NaBH4), PSS, PLL, HA, and trypsin (0.25×)
were purchased from Sigma-Aldrich. Ascorbic acid was
purchased from Fluka. DOXO hydrochloride was purchased
from Calbiochem. All other reagents were of analytical grade
and/or suitable for cell culture, as corresponding. All chemicals
were used as received.
4.2. Synthesis of GNRs. GNRs were synthesized using a
seed-mediated growth method. First, CTAB-capped Au seeds
were obtained. To do that, 7.5 mL of a 0.2 M CTAB solution
was gently mixed with 0.25 mL of 0.01 M HAuCl4 in a water
bath at 27 °C. Next, a 0.01 M NaBH4 solution was prepared in
ice-cold water. This solution was left to rest for 2−3 min to
ensure a good dispersion of the reductant. Afterward, 0.6 mL
of ice-cold 0.01 M NaBH4 was added to the Au−CTAB
solution under stirring at 200 rpm in one pull, after which the
mixed solution turned brownish yellow. This was mixed gently
by hand for 2 min and then left undisturbed in a water bath at
27 °C for 1 h to allow the excess sodium borohydride to be
decomposed.
For the growth of GNRs, 425 μL of a 0.01 M HAuCl4
solution was added to 10 mL of 0.2 M CTAB in a water bath at
27 °C, after which the solution turned yellow bright while
stirred at 500 rpm. Then, a 0.01 M a AgNO3 solution was
prepared in the dark. Different volumes of the silver solution
(ranging from 63 to 143 μL) were added to the Au growth
solution followed by gentle mixing by hand. Then, 68 μL of a
0.1 M ascorbic acid solution was added followed by gentle
stirring at 500 rpm until the solution turned colorless and left it
in this way for 4 min in a water bath at 27 °C. Finally, 110 μL
of the Au seed solution was gently added to the Au growth
solution while stirring for 2 min and then stopped. The
resulting solution was left undisturbed in a water bath
overnight at 27 °C, and the solution turned reddish pink.
The formed GNRs were centrifuged at least twice at 27 °C for
20 min and resuspended in 10 mL of deionized water. The
UV−visible absorption spectra of the obtained GNRs were
measured using a Cary Bio 100 UV−Vis spectrophotometer
(Agilent Technologies, USA). The sizes and aspect ratios of
GNRs were measured using a JEOL JEM 1011 (Japan) TEM
microscope operating at an accelerating voltage of 120 kV.
4.3. Preparation of PE Multilayers onto GNRs.
4.3.1. PSS/DOXO/PLL/HA-Coated GNRs. Using the LbL
method, multilayers of PSS, DOXO, PLL, and HA were
successfully deposited on the GNR surfaces. For PSS coating, a
solution of PSS (10 mg/mL) in 12 mM NaCl was prepared.
When this PE was completely dissolved, 1 mL of this PE
solution was mixed with 1 mL of a 12 mM NaCl solution, and
the resulting mixture was stirred at 500 rpm. Then, the latter
solution was added dropwise to 1 mL of a GNR solution (OD
≈ 1) while stirring. After 1 h of adsorption, the mixture was
centrifuged twice at 15 000 rpm for 20 min and resuspended in
1 mL of Milli-Q water. Next, a solution of DOXO (1 mM) was
prepared in an acetic acid buffer at pH 4.166 to protonate the
drug amino groups for a more efficient LbL electrostatic-based
deposition. DOXO (typically 100 μg) was diluted in 700 μL of
water and stirred at 500 rpm for 5 min. Next, 1 mL of the PSS-
coated GNRs was added dropwise to the DOXO solution
under stirring. After 1 h, the mixture was centrifuged once at
15 000 rpm for 20 min and redispersed in 1 mL of Milli-Q
water. As the PSS/DOXO-coated GNR particles have a
negative surface charge, a subsequent cationic PLL layer can be
used to coat the hybrids. Thus, 100 μL of a PLL solution (5
mg/mL) was added to 1 mL of Milli-Q water and stirred for 5
min. Then, 1 mL of PSS/DOXO-coated GNRs was added
dropwise. After 1 h, the NPs were centrifuged at 15 000 rpm
for 15 min and resuspended in 1 mL of Milli-Q water. The
deposition of the final HA layer was made by preparing 60 μL
of a HA concentrated solution (1 mg/mL), which was mixed
with 1 mL of Milli-Q water and stirred at 500 rpm for 5−10
min. The former PSS/DOXO/PLL-coated GNRs were added
dropwise to the former HA solution. After 1 h, the final coated
GNRs were centrifuged at 15 000 rpm for 10 min and
redispersed in 1 mL of Milli-Q water.
4.3.2. (PSS/DOXO/PLL)2/HA-Coated GNRs. For these
particles, the first three layers corresponding to PSS, DOXO,
and PLL were obtained as previously explained. Next, a second
new PSS layer was formed by mixing 250 μL of the PSS
solution with 750 μL of 12 mM NaCl and stirring at 500 rpm.
Then, 1 mL of PSS/DOXO/PLL-coated GNRs (OD ≈ 1) was
added dropwise while stirring. After 1 h, the mixed solution
was centrifuged once at 15 000 rpm for 20 min and redispersed
in 1 mL of Milli-Q water. Next, 100 μg of DOXO (1 mM) was
mixed with 1 mL of acetic acid buffer and stirred at 500 rpm
for 5 min. (PSS)2/DOXO/PLL-coated GNRs were added to
this solution dropwise under stirring. After 1 h, the mixture was
centrifuged once at 15 000 rpm for 20 min and redispersed in 1
mL of water. Then, 50 μL of a 5 mg/mL PLL solution was
mixed with 1 mL of water and stirred at 500 rpm for 5 min.
Again, 1 mL of (PSS/DOXO)2/PLL-coated GNRs was added
to this PLL solution dropwise under stirring. After 1 h, the
mixture was centrifuged once at 15 000 rpm for 20 min and
redispersed in 1 mL of MilliQ water. The final HA layer
implied the dilution of 60 μL of HA in 1 mL of water and
stirred at 500 rpm for 5−10 min. (PSS/DOXO/PLL/)2-coated
GNRs were then added drop by drop at 500 rpm. After 1 h, the
final hybrid NPs were centrifuged at 15 000 rpm for 10 min
and redispersed in 1 mL of deionized Milli-Q water.
4.4. Dynamic Light Scattering. DLS measurements were
performed using an ALV-5000 digital correlator system (ALV
5000/E, ALV GmbH, Germany) equipped with a temperature
controller set at 25 ± 0.1 °C. The scattered light was vertically
polarized with a 488 nm solid-state laser (2 W). The
hydrodynamic radius, RH, was obtained for diluted samples
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from DLS measurements at an incidence angle of 90° by
analysis of the DLS data by means of the CONTIN algorithm
developed by Provencher67 and the Stokes−Einstein equation,
RH = kBT/6πηD, where kB is the Boltzmann constant, T is the
temperature, η is the solution viscosity, and D is the diffusion
coefficient of the particles. Measurements were performed at
least in triplicate with a sampling time of 60 s each and
averaged.
4.5. Electrophoretic Mobilities. ζ-Potentials of bare and
PE-coated GNRs were measured using Nano ZS (Nanoseries,
Malvern Instruments, UK). The instrument measures the
electrophoretic mobility of the particles and converts it into ζ-





where α, ε, ζ, and η denote the electrophoretic mobility,
permittivity of the medium, ζ-potential of the particles, and
viscosity, respectively. Each sample was fed into a folded
capillary, clear, disposable cell. Measurements were initiated
after thermal equilibration at 25 °C. The number of runs was
automatically determined by the software, and measurements
were performed in triplicate. The results were reported as the
mean ± SD.
4.6. Quantitative Analysis of DOXO Loading. To
determine the EE and LC of DOXO within PSS/PLL/DOXO/
HA-coated and (PSS/PLL/siRNA)2/HA-coated GNRs, the
hybrid NPs were centrifuged at 15 000 rpm at 20 °C for 20
min. The DOXO content in the supernatant was measured by
means of UV−vis and fluorescent spectroscopies. Previously, a
calibration curve with free DOXO was obtained, and the
absorbance/fluorescence of supernatants of bare GNR
solutions was also considered as an additional blank. UV−vis
measurements were made at 488 nm. The fluorescence
standard curves were set at λex = 480 nm and collected at
λem = 560−590 nm. UV−vis spectra were measured in a Cary
Bio 100 UV−vis spectrophotometer (Agilent Technologies,
USA). Fluorescence spectra were monitored in a Cary Eclipse
spectrophotometer (Agilent Technologies, USA). Each sample
was measured in triplicate for three different batches. The EE
and LC were calculated by the following expressions
EE (%)
total amount of DOXO feeded DOXO in supernatant






total amount of DOXO feeded DOXO in supernatant





4.7. Inductively Coupled Plasma Mass Spectrometry.
The Au concentration in solution or in cells was determined by
inductively coupling plasma mass spectrometry in a Varian
820-MS equipment (Agilent Technologies, USA). One
milliliter of 1 × 1011 GNRs/mL (or 100 000 cells with NPs
where corresponding) was dissolved in 0.3 mL of HCl [37%
(v/v)] and 0.1 mL of HNO3 [70% (v/v)]. The solutions were
diluted with deionized water until reaching a final volume of 2
mL. The intensity of the emission wavelength was measured
and compared to a standard solution.
4.8. In Vitro Release Experiments. DOXO cumulative
release profiles from the hybrid NPs were measured in vitro at
a constant temperature of 37 °C at 300 rpm magnetic stirring
for several days at pHs 7.4 and 5.5. To obtain the release
profiles, 1 mL of hybrid GNRs was placed into dialysis tubes
(SpectraPore, MWCO 3500) and immersed into 50 mL of
buffer supplemented with 10% (v/v) FBS at the pH of interest.
The released DOXO concentration was determined at different
time intervals for each solution pH. At each sampling time, 1
mL of the medium was withdrawn and replaced with the same
volume of fresh buffer to maintain the required sink conditions.
The DOXO content was measured by means of UV−vis and
fluorescence using previously established calibration curves in
the corresponding buffers. UV−vis spectra were measured in a
Cary Bio 100 UV−vis spectrophotometer (Agilent Technol-
ogies, USA), and the fluorescence spectra were monitored in a
Cary Eclipse spectrophotometer (Agilent Technologies, USA).
Assays were carried out in triplicate.
4.8.1. Protease-Assisted DOXO Release. The enzyme-
triggered DOXO release from GNRs (1 mL, 1 × 1011 NP/
mL) was measured in vitro at a constant temperature of 37 °C
under moderate magnetic stirring (300 rpm) for several days at
pHs 7.4 and 5.5 in the presence and absence of trypsin−
ethylenediaminetetraacetic acid (50 μL per 40 mL of buffer).
Hybrid GNRs (1 mL) were placed into dialysis tubes
(SpectraPore, MWCO 3500) and immersed into 50 mL of
buffer supplemented with 10% (v/v) FBS and the suitable
amount of trypsin at the pH of interest. The released DOXO
concentrations were determined as explained above.
4.8.2. NIR Light-Triggered DOXO Release. To analyze the
effect of the laser exposure on DOXO release from GNRs, 1
mL (1 × 1011 NP/mL) of these hybrid NPs was incubated at
37° C under moderate stirring at pH 5.5. The experimental
conditions were similar as those previously stated in the
absence of trypsin, except for after 6 and 24 h of incubation
GNRs, which were exposed to NIR light irradiation of 0.5 and
3 W/cm2 for 5 min. Irradiation was performed using a CW
fiber-coupled diode laser source at 808 nm wavelength (50 W,
Oclaro, Inc., San Jose, CA). The laser was powered by a
Newport 5700-80 laser diode driver (Newport Corporation,
Irvine, CA). A 200 μm core optical fiber was used to transfer
the laser power from the laser unit to the particle solution and
connected with a lens telescope mounting accessory at the
output, which allowed for fine-tuning the laser spot size in the
range of 1−10 mm. The output power was independently
calibrated using an optical power meter (Newport 1916-C)
and the laser spot size was previously measured with a laser
beam profiler (Newport LBP-1-USB), which was placed at the
same distance (8 cm) between the lens telescope output and
the sampling cuvette.
4.9. Tumor Cells. Cervical HeLa and breast MDA-MB-231
cancer cells from Cell Biolabs (San Diego, CA) were grown at
standard culture conditions (5% CO2 at 37 °C) in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10%
(v/v) FBS, 2 mM L-glutamine, 1% (v/v) penicillin/
streptomycin, 1 mM sodium pyruvate, and 0.1 mM MEM
nonessential amino acids.
4.10. Cellular Uptake by TEM. HeLa cells were seeded in
6-well plates (2 mL, 5 × 104 cells per well) and grown for 24 h
at standard culture conditions. Then, 200 μL (2.5 × 1010 NP/
mL) was added to cells. After 6 h of incubation, the NP-
containing cells were washed three times with phosphate-
buffered saline (PBS), trypsinized, and centrifuged at 1500 rpm
for 4 min. The cell pellets were fixed with 500 μL of 2.5% (w/
v) glutaraldehyde and then included in an agar pellet, post-
fixed with osmium tetraoxide in 0.1 M cacodylate buffer at 1%
(w/v), and, finally, pelletized with Eponate (Ted Pella Inc,
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Redding, CA, USA). Ultrathin cuts were obtained with an
ultramicrotome (UltraCut S, Leica Microsystems GmbH) and
analyzed with a TEM microscope (JEOL JEM 1011, Japan).
4.11. Cellular Uptake and DOXO Release by Fluo-
rescence Microscopy. Particle uptake and DOXO release
inside cells were also followed by fluorescence microscopy.
HeLa cells were seeded on poly-L-lysine coated glass coverslips
(12 × 12 mm2, Sigma-Aldrich) placed inside 6-well plates (2 ×
105 cells per well) with 2 mL of DMEM and grown for 24 h at
standard culture conditions. Then, PSS/PLL/DOXO/HA-
coated and (PSS/PLL/DOXO)2/HA-coated GNRs (2.5 ×
1010 NP/mL, 250 μL) were added to cells. After 6 h of
incubation, the cells were washed three times with PBS and
fresh medium was added. Next, some cells were irradiated with
a CW 808 nm fiber-coupled diode laser source (50 W, Oclaro
Inc., San Jose, CA) for 5 min at 0.5 W/cm2. After the desired
incubation time (4, 6, 8, 12, and 24 h), the cells were washed
three times with PBS, fixed with 4% (w/v) paraformaldehyde
for 10 min, washed again with PBS, treated with Triton X-100
for 10 min, and, finally, washed again with PBS. Then, the
coverslips were mounted on glass slides, stained with DAPI
(Invitrogen, USA) and cured for 24 h at −20 °C. The samples
were visualized at 63× using a wide field fluorescence inverted
microscope (Leica DMI6000B, Leica Microsystems, Germany)
using the blue channel for DAPI (λex = 350 nm), the red
channel for DOXO (λex = 520 nm), and transmitted light in
differential interference contrast mode.
4.12. In Vitro Cell Cytotoxicity. The cytotoxicity of the
present DOXO-loaded GNRs was tested in vitro by the CCK-8
proliferation assay. Cervical HeLa and breast MDA-MB-231
cancer cells at an optical confluence of 80−90% were seeded
into 96-well plates (100 μL, 1.0 × 104 cells/well) and grown
for 24 h at standard culture conditions in 100 μL of the growth
medium. After 24 h of incubation at 37 °C and 5% CO2, 100
μL of a 2.5 × 1010 NP/mL solution of PSS/PLL/DOXO/HA-
coated and (PSS/PLL/DOXO)2/HA-coated GNRs were
diluted in the corresponding cell culture medium and then
injected into the wells and incubated for 6 h. Free DOXO was
used as a control at a molar concentration equivalent to the
total drug loaded in PSS/PLL/DOXO/HA-coated GNRs.
After the corresponding incubation period (24 or 48 h), the
culture medium was discarded, cells were washed with PBS
(pH 7.4) and fresh culture medium (100 μL) was added, the
culture medium was discarded, the cells were washed again
with 10 mM PBS, and new culture medium (100 μL) was
added containing 10 μL of the CCK-8 reagent to each well.
After 2 h of incubation, the absorbance at 450 nm of cell
samples was measured with a UV−vis microplate absorbance







where Abs sample is the absorbance at 450 nm for samples
with NPs and Abs blank is the absorbance for controls without
NPs.
In addition, some of the wells were also irradiated with a
CW fiber-coupled diode laser source at 808 nm (50 W, Oclaro,
Inc., San Jose, CA). The used power fluencies were 0.5, 1.0,
and 3.0 W/cm2 for 5 min. After 18 and 42 h, the cells were
washed again and new fresh culture medium (100 μL) was
added with 10 μL of the CCK-8 reagent to each well and
measured as specified above.
4.13. Annexin V/Dead Cell Apoptosis Assay. HeLa and
MDA-MB-231 cells were treated with PSS/DOXO/PLL/HA-
coated, (PSS/DOXO/PLL)2/HA-coated, and PSS/PLL/HA-
coated GNRs and with 2 μg/mL of free DOXO as a positive
control for apoptosis. Untreated cells were used as a negative
control. After 6 h of incubation with the hybrid NPs or free
DOXO, the culture medium was changed by fresh one and
cells were illuminated with an 808 nm CW laser at several
power intensities (0, 0.5, 1, and 3 W/cm2) for 5 min. After 24
h, the cells were trypsinized and redispersed in 500 μL of fresh
medium (7.5 × 104 cells/mL). Then, 100 μL of cells was
mixed with 100 μL of the Annexin V/Dead cell reagent (Muse
Annexin V & Dead Cell Assay Kit, Millipore, USA) and
incubated for 20 min in the dark at room temperature. Finally,
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